



ASX Announcement

27 October 2022

2022 Annual General Meeting – Chairman’s Address

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (**Atomo**) attaches the Chairman’s Address to be delivered at Atomo’s 2022 Annual General Meeting.

For more information, please contact:

John Kelly

Atomo Diagnostics

john.kelly@atomodiagnostics.com

Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.



On behalf of my fellow directors, I welcome you warmly to Atomo Diagnostics' (**Atomo**) Annual General Meeting for 2022.

We gather in person on the lands of the Gadigal People of the Eora Nation, the Eora lands reach west to the Nepean, south to the Georges River and north to the Hawkesbury. To my fellow New Zealanders tena kotu, tena kotu, katoa.

I am joined by fellow directors, our company secretary, auditor, external counsel and Atomo's senior executives.

I will shortly ask for your involvement in considering a number of resolutions.

Let me first talk about Atomo's financial year to June 30 2022, and then about the year ahead, inviting John Kelly, Atomo's CEO and Managing Director, to discuss both in further detail.

It is with considerable relief that we see signs of the COVID 19 pandemic easing. As a community, our accelerated adoption of rapid diagnostics allowed decentralised testing to serve us all as a first line of screening.

In the hands of individuals, rapid testing reflects people exercising a greater level of control over their health, strongly complementing established testing in clinical settings. In the workplace, employers deployed rapid tests as a fundamental aspect of assisting their staff's well-being. Atomo played an important role in supplying more than 1 million rapid covid tests.

The public health response to COVID-19 accelerated profound changes in the use of rapid diagnostics. These changes are enabled by decentralising diagnostics and sample collection without a loss of accuracy in results. Atomo's longstanding belief and so our strategy is to fundamentally improve the availability, speed and accuracy of rapid diagnostics.

For those who are our newer shareholders, let me talk more about what we do in rapid diagnostics. Atomo develops, commercialises and supplies devices for rapid diagnostic tests. We sell finished rapid tests for professional users and consumers. Our tests detect infectious diseases, chronic health conditions, and consumer wellness.

Atomo participates in three identified markets in the development and commercialisation of diagnostic devices. These markets are infectious disease testing, OEM+ devices, and consumer health and wellness.

Each of these markets involves Atomo's scale deployment of our patented technologies, often through partnering.

Let me start with infectious diseases. Locally during the 2022 financial year, we began partnering with the Australian Pharmacy Guild, making our Rapid HIV Self Tests available over the counter. This arrangement followed the Therapeutic Goods Administrator widening approved sales guidelines beyond the more discreet online sales channel.

In global health, our continuing relationship with Viatrix Inc sees growing in-country approvals permitting the marketing of our HIV tests, especially amongst developing countries. In the OEM+ market, during the year we supplied devices to NG Biotech, Access Biotech, and Lumos Diagnostics to house their proprietary rapid tests.

Our third market, consumer health and wellness, is changing quickly. We view the accelerated adoption of rapid diagnostics during the COVID-19 pandemic as a watershed moment in the decentralising of screening diagnostics. This conclusion is supported by the extent of user take-up and acceptance by regulators and public health authorities.



Atomo's product development continued throughout the year. We excitedly announced the extension of our diagnostics products, adding swab and saliva devices to our blood-based lateral flow device collection. As with all Atomo products, the design of these new devices prioritise ease of use and accuracy of results for users, their mechanisms incorporating essential Atomo IP. Atomo's extended portfolio valuably underpins our engagement with existing and prospective partners. John will shortly share with you how we are positioning in the decentralisation of diagnostics and sample collection, and our devices' role.

Our planning for the 2023 year drew partly from what we discussed during our last AGM, including the appointment of senior executives and directors. We are delighted to have welcomed San Diego based Jim McMenemy as Head of Business Development and Partnerships, and London based Anna Tucker as Vice President Development for EMEA. We celebrated Chandra Sukumar's promotion to COO following an extensive external and internal search. We thank UK-based Mark Smith as Mark retired as our longstanding COO.

On behalf of Atomo's Board and Management, we gratefully acknowledge the tireless efforts of those who provide services and advice to Atomo - Tharun Kuppana our Company Secretary of Board Room, Grant Hummel of HWLE, Gareth Few of BDO, Canaccord, Bell Potter and Alex Munro.

Atomo's Board of Directors shares substantial commercial, governance, and industry experience across the critical aspects of our business. Amongst the Board's priorities is ensuring that we have the capabilities and domain expertise to govern our global business effectively. As a Board, we review our composition to ensure we have the rights skills and experience to deliver shareholder value.

The balance of our Board comprises Deborah Neff, Paul Kasian, Curt LaBelle, John Kelly, and me. Deborah chairs our People, Culture and Remuneration Committee, and Paul chairs Audit and Risk, pillars of our corporate governance. I sit on both Committees.

You will be shortly asked to consider Paul Kasian and me for re-election to Board, in keeping with Atomo's Board process.

In closing, I share the Board's strong recognition of the Atomo team's commitment to developing and implementing the company's strategy, while making sense of, and realising new opportunities. John Kelly's tireless leadership, his executive team of Will Souter CFO, Chandra Sukumar COO, Jim McMenemy and Anna Tucker lead our work with partners and customers.

The decentralisation of health services, diagnostics and care, accelerated with the COVID-19 pandemic. The adoption of rapid diagnostics has changed users' behaviours and expectations of testing by location, speed to results and timelier prescription. These changes align with Atomo's proven competencies. Atomo's competitive positioning draws from our product and commercialisation expertise. We are excited about this year and those ahead. I welcome John to talk about what we are up to in further detail. Thank you for your enthusiastic support, questions, and interest in Atomo.

- END -